UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration

European journal of cancer (1990), 2023-09, Vol.190, p.112950-112950, Article 112950

2023

Volltextzugriff (PDF)

Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma

Clinical lymphoma, myeloma and leukemia, 2020-11, Vol.20 (11), p.749-756.e1

2020

Volltextzugriff (PDF)

Stimulation of Polo-Like Kinase 3 mRNA Decay by Tristetraprolin

Molecular and Cellular Biology, 2009-04, Vol.29 (8), p.1999-2010

2009

Volltextzugriff (PDF)

Patients with relapsed follicular lymphoma treated with rituximab versus tositumomab and iodine I-131 tositumomab

Leukemia & lymphoma, 2015-03, Vol.56 (3), p.779-781

2015

Volltextzugriff (PDF)

Long-term follow-up of previously treated and treatment-naïve patients who received tositumomab and I-131 tositumomab

Leukemia & lymphoma, 2016-05, Vol.57 (5), p.1238-1240

2016

Volltextzugriff (PDF)

Species-Specific Differences in Expression of G-Protein-Coupled Receptor Kinase (GRK) 7 and GRK1 in Mammalian Cone Photoreceptor Cells: Implications for Cone Cell Phototransduction

The Journal of neuroscience, 2001-12, Vol.21 (23), p.9175-9184

2001

Volltextzugriff (PDF)

CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma

Clinical lymphoma, myeloma and leukemia, 2016-04, Vol.16 (4), p.191-196

2016

Volltextzugriff (PDF)

Phosphorylation of GRK1 and GRK7 by cAMP-dependent Protein Kinase Attenuates Their Enzymatic Activities

The Journal of biological chemistry, 2005-08, Vol.280 (31), p.28241-28250

2005

Volltextzugriff (PDF)

Organized Endothelial Cell Surface Signal Transduction in Caveolae Distinct from Glycosylphosphatidylinositol-anchored Protein Microdomains

The Journal of biological chemistry, 1997-03, Vol.272 (11), p.7211-7222

1997

Volltextzugriff (PDF)

Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors

Clinical cancer research, 2019-12, Vol.25 (24), p.7331-7339

2019

Volltextzugriff (PDF)

A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer

Clinical cancer research, 2024-01, Vol.30 (2), p.334-343

2024

Volltextzugriff (PDF)

Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open‐label, dose escalation study

International journal of cancer, 2022-03, Vol.150 (6), p.993-1006

2022

Volltextzugriff (PDF)

Abstract CT104: A first-in-human phase I dose escalation study of BET inhibitor GSK2820151 in patients with advanced or recurrent solid tumors cancers

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT104-CT104

2017

Volltextzugriff (PDF)

Endothelin Induces Rapid, Dynamin-mediated Budding of Endothelial Caveolae Rich in ET-B

The Journal of biological chemistry, 2012-05, Vol.287 (21), p.17353-17362

2012

Volltextzugriff (PDF)

Observational Retrospective Study of Altered Biodistribution of Tositumomab and sigma up 131 member of -Tositumomab

The Journal of nuclear medicine (1978), 2015-11, Vol.56 (11), p.1800-1800

2015

Volltextzugriff (PDF)

Observational Retrospective Study of Altered Biodistribution of Tositumomab and 131 I-Tositumomab

Journal of Nuclear Medicine, 2015-11, Vol.56 (11), p.1800-1803

2015

Volltextzugriff (PDF)

Observational Retrospective Study of Altered Biodistribution of Tositumomab and ^sup 131^I-Tositumomab

The Journal of nuclear medicine (1978), 2015-11, Vol.56 (11), p.1800

2015

Volltextzugriff (PDF)

BET inhibitor molibresib for the treatment of advanced solid tumors: Final results from an open-label phase I/II study

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3618-3618

2020

Volltextzugriff (PDF)

Abstract CT038: A phase I, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of GSK3326595 in subjects with solid tumors and non-Hodgkin's lymphoma

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT038-CT038

2017

Volltextzugriff (PDF)

A phase I, open-label study of GSK2816126, an enhancer of zeste homolog 2 (EZH2) inhibitor, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), other non-Hodgkin’s lymphomas (NHL), multiple myeloma (MM) and solid tumor

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS2595-TPS2595

2016

Volltextzugriff (PDF)

A Phase II study of iodine-131 tositumomab plus chemotherapy in patients with previously untreated mantle cell lymphoma

Clinical lymphoma, myeloma and leukemia, 2019-04, Vol.20 (11), p.749-756.e1

2019

Volltextzugriff (PDF)

A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects with Relapsed, Refractory Hematologic Malignancies

Blood, 2016-12, Vol.128 (22), p.5223-5223

2016

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(33)

Publikationsform

Sprache

Englisch
(38)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(18)
Life Sciences & Biomedicine
(16)
Humans
(12)
Oncology
(11)
Adult
(6)
Female
(6)
Male
(6)
Aged
(5)
Animals
(5)
Hematology
(5)
Middle Aged
(5)
Adolescent
(4)
Antineoplastic Agents - Therapeutic Use
(4)
Biochemistry & Molecular Biology
(4)
Aged, 80 And Over
(3)
Antibodies, Monoclonal - Therapeutic Use
(3)
Treatment Outcome
(3)
Young Adult
(3)
Antineoplastic Agents - Adverse Effects
(2)
Antineoplastic Agents - Pharmacokinetics
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors

Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma

Stimulation of Polo-Like Kinase 3 mRNA Decay by Tristetraprolin

Patients with relapsed follicular lymphoma treated with rituximab versus tositumomab and iodine I-131 tositumomab

Long-term follow-up of previously treated and treatment-naïve patients who received tositumomab and I-131 tositumomab

Species-Specific Differences in Expression of G-Protein-Coupled Receptor Kinase (GRK) 7 and GRK1 in Mammalian Cone Photoreceptor Cells: Implications for Cone Cell Phototransduction

CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma

Phosphorylation of GRK1 and GRK7 by cAMP-dependent Protein Kinase Attenuates Their Enzymatic Activities

Organized Endothelial Cell Surface Signal Transduction in Caveolae Distinct from Glycosylphosphatidylinositol-anchored Protein Microdomains

Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors

A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer

Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open‐label, dose escalation study

A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies

Abstract CT104: A first-in-human phase I dose escalation study of BET inhibitor GSK2820151 in patients with advanced or recurrent solid tumors cancers

Endothelin Induces Rapid, Dynamin-mediated Budding of Endothelial Caveolae Rich in ET-B

Observational Retrospective Study of Altered Biodistribution of Tositumomab and sigma up 131 member of -Tositumomab

Observational Retrospective Study of Altered Biodistribution of Tositumomab and 131 I-Tositumomab

Observational Retrospective Study of Altered Biodistribution of Tositumomab and ^sup 131^I-Tositumomab

BET inhibitor molibresib for the treatment of advanced solid tumors: Final results from an open-label phase I/II study

Abstract CT038: A phase I, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of GSK3326595 in subjects with solid tumors and non-Hodgkin's lymphoma

A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)

A phase I, open-label study of GSK2816126, an enhancer of zeste homolog 2 (EZH2) inhibitor, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), other non-Hodgkin’s lymphomas (NHL), multiple myeloma (MM) and solid tumor

A Phase II study of iodine-131 tositumomab plus chemotherapy in patients with previously untreated mantle cell lymphoma

A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects with Relapsed, Refractory Hematologic Malignancies

Suchergebnisse filtern